Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v2.4.0.6
Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 81 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2013
Operating expenses:      
Research and development $ 5,974 $ 4,581 $ 47,983
General and administrative 2,484 2,000 18,763
In-process research and development       21,749
Loss from operations (8,458) (6,581) (88,495)
Interest income 76 44 556
Interest expense (476) (19) (4,429)
Other income       733
Warrant expense       (1,407)
Net loss (8,858) (6,556) (93,042)
Common Stock dividend to Series A Convertible Preferred Stockholders       (5,861)
Net loss attributed to Common Stock $ (8,858) $ (6,556) $ (98,903)
Basic and diluted net loss per common share $ (0.35) $ (0.35)  
Weighted average common shares outstanding - basic and diluted 25,182,369 18,604,245